---
title: "Cardio Diagnostics Holdings (NASDAQ: CDIO) Targets a $393B Heart Disease Problem with Epigenetics and AI"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290596938.md"
description: "Cardio Diagnostics Holdings (NASDAQ: CDIO) Targets a $393B Heart Disease Problem with Epigenetics and AI"
datetime: "2026-06-23T18:00:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290596938.md)
  - [en](https://longbridge.com/en/news/290596938.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290596938.md)
generator: "portal-rs"
---

# Cardio Diagnostics Holdings (NASDAQ: CDIO) Targets a $393B Heart Disease Problem with Epigenetics and AI


### Related Stocks

- [CDIO.US](https://longbridge.com/en/quote/CDIO.US.md)
- [CDIOW.US](https://longbridge.com/en/quote/CDIOW.US.md)

## Related News & Research

- [Cardio Diagnostics report flags widening rural cardiovascular care gap as workforce shortages persist](https://longbridge.com/en/news/297046313.md)
- [Cardio Diagnostics Holdings (NASDAQ: CDIO) Leverages Epigenetics to Reveal Hidden Heart Disease Risks](https://longbridge.com/en/news/291318866.md)
- [Alnylam announces new data at ESC Congress on AMVUTTRA](https://longbridge.com/en/news/297453980.md)
- [Is Walmart Stock Underperforming the Nasdaq?](https://longbridge.com/en/news/297403545.md)
- [Quiron study REACT finds 57.1% of adults without known heart disease have silent atherosclerosis](https://longbridge.com/en/news/297484267.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**